Chimeric antigen receptor (CAR) T-cell therapy has achieved substantial clinical outcomes
for tumors, especially for hematological malignancies. However, extending the duration of …

Chimeric antigen receptor (CAR) T cells have shown significant efficacy in hematological
diseases. However, CAR T therapy has demonstrated limited efficacy in solid tumors …

Successful implementation of adoptive cell therapy (ACT) of cancer requires
comprehensively addressing biological and practical challenges. This approach has been …

Most anti-cancer modalities are designed to directly kill cancer cells deploying mechanisms
of action (MOAs) centered on the presence of a precise target on cancer cells. The efficacy …

CAR T cell therapy, hailed as a breakthrough in cancer treatment due to its remarkable
outcomes in hematological malignancies, encounters significant hurdles when applied to …

We have developed a chimeric antigen receptor (CAR) against the six-transmembrane
epithelial antigen of prostate-1 (STEAP1), which is expressed in prostate cancer, Ewing …

Simple Summary The ectopic expression of the master regulator PU. 1 could prove
detrimental to CAR T cell functionality despite its upregulation of multiple costimulatory …

The application of chimeric antigen receptor (CAR) T cells in the management of
hematological malignancies has emerged as a noteworthy therapeutic breakthrough …

Given that CAR-T cell therapy is effective in CD19-positive blood malignancies, it offers
great hope for a variety of aggressive tumors that have thus far shown very little response to …